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Broadly neutralizing antibodies (bNAbs) against
HIV-1 provide both effective pre-exposure prophy-
laxis and treatment of HIV-1 infection in murine and
nonhuman primate models, suggesting their poten-
tial use in humans. Although much is known about
the role of variable domains in the neutralization
breadth and potency of these bNAbs, the contribu-
tion of Fc domains to their activities is, by contrast,
poorly characterized. Assessment of the in vivo ac-
tivity of several bNAbs revealed that FcgR-mediated
effector function contributes substantially to their ca-
pacity to block viral entry, suppress viremia, and
confer therapeutic activity. Enhanced in vivo potency
of anti-HIV-1 bNAbs was associated with preferential
engagement of activating, but not inhibitory FcgRs,
and Fc domain-engineered bNAb variants with selec-
tive binding capacity for activating FcgRs displayed
augmented protective activity. These findings reveal
key roles for Fc effector function in the in vivo activity
of anti-HIV-1 bNAbs and provide strategies for
generating bNAbs with improved efficacy.
INTRODUCTION
Passive administration of antibodies directed against the enve-
lope protein (Env) of HIV-1 represents a promising mode of clin-
ical intervention for this disease as a result of the recent isolation
and characterization of human antibodies with exceptionally
broad and potent neutralizing activity (Klein et al., 2013; Scheid
et al., 2009; Walker et al., 2011). Passive administration of these
anti-HIV-1 broadly neutralizing antibodies (bNAbs) has been
shown to confer sterilizing immunity against virus containing
elements of HIV and SIV (SHIV) challenge in macaques and
HIV-1 infection in humanized mouse models (Balazs et al.,
2012; Hessell et al., 2007; Mascola et al., 2000). Furthermore,
effective control of viral replication in HIV-1-infected humanizedCmice and in SHIV-infected nonhuman primates by bNAbs clearly
suggested their potential use as a therapeutic modality for hu-
man HIV-1 infection (Barouch et al., 2013; Horwitz et al., 2013;
Klein et al., 2012b; Shingai et al., 2013).
Although the neutralizing activity of an antibody has been
commonly considered to be the result of Fab-antigen interac-
tions that block viral entry, substantial evidence suggests that
the in vivo activity of an antibody is highly dependent upon inter-
actions of the immunoglobulin G (IgG) fragment crystallizable
(Fc) domain with its cognate receptors, Fcg receptors (FcgR) ex-
pressed on the surface of effector leukocytes (Abboud et al.,
2010; Bournazos et al., 2014; Corti et al., 2011; DiLillo et al.,
2014; Li and Ravetch, 2011; Nimmerjahn and Ravetch, 2005;
Smith et al., 2012). The FcgR system represents a balance of
activating and inhibitory receptors that transduce immunostimu-
latory or immunomodulatory signals following engagement with
IgG immune complexes, determining thereby the outcome of
IgG-mediated inflammation and immunity (Pincetic et al.,
2014). Indeed, selective engagement of activating or inhibitory
FcgRs by IgG has been shown to determine the in vivo outcome
of antibody treatment, suggesting that Fc-mediated pathways
play a key role in modulating the effector activity of a monoclonal
antibody (mAb) (Li and Ravetch, 2011; Nimmerjahn and Ravetch,
2005). For example, the neutralizing activity of antitoxin and anti-
viral antibodies has been demonstrated to require selective
FcgR engagement to mediate their in vivo protective activities
(Akiyoshi et al., 2010; Bournazos et al., 2014; Corti et al., 2011;
DiLillo et al., 2014).
Although the potential involvement of FcgR effector pathways
in antibody-mediated protection against HIV-1 has been previ-
ously discussed in numerous studies (Ackerman et al., 2013;
Forthal et al., 2010, 2011; Lai et al., 2014; Perez et al., 2013),
there is still very limited evidence on the exact contribution of
Fc effector function in the protective activity of anti-HIV-1
mAbs, stemming from the lack of an in vivo model system that
recapitulates FcgR functional and structural diversity. Indeed,
the use of artificial in vitro systems for the study of Fc effector
function poorly reflects the diversity and complexity of in vivo
FcgR-mediated pathways, providing thereby limited information
on the precise Fc effector mechanisms that mediate viralell 158, 1243–1253, September 11, 2014 ª2014 Elsevier Inc. 1243
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Figure 1. Generation and Characterization
of Mouse-Human Chimeric Anti-HIV-1
mAbs with Differential FcgR Binding Profile
Mouse-human anti-HIV-1 mAbs were generated
by replacing the constant region of the heavy chain
(CH1–3) of human IgG1 (parental IgG subclass)
with that of mouse IgG1 or mouse IgG2a. A null
FcgR binding variant of mouse IgG1 (mIgG1
D265A) was also generated.
(A and B) (A) Relative FcgR binding profile (as as-
sessed by SPR analysis [Table S1]) for the various
mouse IgG Fc subclass variants. The affinity of
mouse-human chimeric Fc domain variants of
anti-HIV-1 mAbs for recombinant gp140YU-2 was
determined by SPR analysis, and representative
SPR sensograms for 1-74 mAb (B) are presented
(gp140 concentration ranging from 31.25 to
1,000 nM). Affinity kinetics measurements for all
the other anti-HIV mAbs are presented in Table S2.
(C) The capacity of Fc domain variants of mouse-
human anti-HIV-1 mAbs to bind to HEK293T cells
expressing gp160DctYU2 was assessed by flow
cytometry. GFP-expressing HEK293T cells (GFP)
were used to determine background mAb binding.
Data represent the geometric mean fluorescence
intensity (Geo MFI) from three independent ex-
periments. See also related Figure S1.
(D) In vitro neutralization activity of mouse-human
anti-HIV-1 mAbs against HIV-1YU-2 was deter-
mined by a standardized TZM-bl assay (Montefiori,
2005), and IC50 values are presented (see also
Table S3).neutralization in vivo. To assess the contribution of Fc-mediated
interactions in the in vivo activity of anti-HIV-1 bNAbs, we utilized
recently developed mouse models for HIV-1 entry (Pietzsch
et al., 2012) and infection (Baenziger et al., 2006; Klein et al.,
2012b; Traggiai et al., 2004). Thesemodels have been previously
characterized extensively and used to successfully assess the
capacity of several anti-HIV-1 bNAbs to inhibit HIV-1 entry
(Pietzsch et al., 2012) or suppress viremia in vivo (Horwitz
et al., 2013; Klein et al., 2012b). Furthermore, the immunothera-
peutic potential of anti-HIV-1 bNAbs against HIV-1 infection in
these murine infection models has been shown to correlate
with nonhuman primates (Barouch et al., 2013; Shingai et al.,
2013), supporting their use for the preclinical evaluation of anti-
HIV-1 bNAbs intended for human HIV-1 prevention or therapy.
In the present study, we assessed the role of Fc effector func-
tion in the in vivo protective activity of several anti-HIV-1 bNAbs
targeting different epitopes on the HIV-1 Env protein. We found
that FcgR-mediated effector function contributes significantly
to their in vivo activity and clearly demonstrated that preferential
engagement of activating FcgRs substantially augmented the
in vivo protective activity of anti-HIV-1 bNAbs. Fc domain engi-
neering of anti-HIV-1 bNAbs to selectively enhance their capac-
ity to interact with activating FcgRs resulted in a substantial
augmentation of their in vivo activity when assessed in an in vivo
model of HIV-1 entry (Pietzsch et al., 2012), as well as in models
ofmAb-mediated therapy usingHIV-1-infected humanizedmice.1244 Cell 158, 1243–1253, September 11, 2014 ª2014 Elsevier Inc.RESULTS
Generation and Characterization of Mouse-Human
Chimeric Anti-HIV-1 bNAbs for the Study of In Vivo Fc
Effector Activity
Because the binding specificity of the Fc region to the respective
FcgRs is species specific, we generatedmouse-human chimeric
versions of several anti-HIV-1 bNAbs in which the constant re-
gion of the heavy chain (CH1-3; human IgG1) was replaced
with that of different mouse IgG Fc subclass variants that exhibit
differential and selective binding capacity for activating or inhib-
itory mouse FcgRs (Figure 1A and Table S1 available online)
(Nimmerjahn and Ravetch, 2005). This approach has been previ-
ously exploited to dissect the individual contribution of activating
or inhibitory FcgR-mediated pathways in the in vivo activity of
protective and immunomodulatory antibodies (DiLillo et al.,
2014; Li and Ravetch, 2011). We have additionally generated a
mouse IgG1 variant (D265A) with diminished binding to all clas-
ses of FcgRs for the assessment of Fc effector function in the
in vivo anti-HIV-1 bNAb activity.
A number of anti-HIV-1 bNAbs were selected targeting various
epitopes of HIV-1 Env, exhibiting variable degree of in vitro
neutralization breadth and potency (Table S3 and Figure 1D).
These included the anti-CD4 binding site (CD4bs) monoclonal
antibodies (mAbs) 3BNC117 (Scheid et al., 2011), 3BNC60
(Scheid et al., 2011), and 1-74 (Scheid et al., 2009); 3BC176, a
mAb recognizing a conformational V3/CD4i epitope (Klein et al.,
2012a); PG16, an anti-V1/2 mAb (Walker et al., 2009); and the
anti-V3 mAbs 1-79 (Scheid et al., 2009) and PGT121 (Pejchal
et al., 2011; Walker et al., 2011). A non-HIV-1 reactive mAb
(mGO53 [Wardemann et al., 2003]) was included as control.
Mouse-human chimeric mAbs were expressed in mammalian
cells (HEK293T cells) and characterized in terms of antigen spec-
ificity by ELISA (Figure S1), by surface plasmon resonance (Fig-
ure 1B and Table S2) using recombinant gp140, and by flow
cytometry using gp160-expressing cells (gp160Dct [deleted
cytoplasmic tail]-HEK293T cells) (Figure 1C) to ensure that
changes in the Fc domain had no impact on their capacity for
Fab-mediated antigen recognition, an effect that was previously
described for other (not anti-HIV-1) mAbs (Casadevall and
Janda, 2012). Although these mouse Fc domain variants ex-
hibited differential capacity to engage mouse FcgRs (Table S1
and Figure 1A), no differences in their antigen affinity and spec-
ificity were observed. Furthermore, no differences in the in vitro
neutralization activity were evident among the various mouse
IgG subclass variants (Table S3 and Figure 1D).
The In Vivo Protective Activity of Anti-HIV-1 bNAbs Is
Dependent upon FcgR Engagement
Given the differential capacity of the mouse-human chimeric
IgG subclass variants of anti-HIV-1 bNAbs to engage particular
classes of FcgRs, comparison of their in vivo activity would
determine the specific contribution of particular FcgR classes
required for optimal mAb in vivo function. Using a recently
described mouse model of HIV-1 entry (Pietzsch et al., 2012)
that is based on a principle closely related to the well-estab-
lished in vitro TZM-bl neutralization assay (Montefiori, 2005),
we assessed the in vivo activity of the various mouse sub-
class variants of anti-HIV-1 bNAbs. As determined previously
(Pietzsch et al., 2012), in vivo infection of luciferase reporter
mice (ROSA-Luc) with HIV-1 Cre pseudovirus was accom-
plished by administration of adenoviral particles (1011, intrave-
nous [i.v.], 48 hr prior to HIV-1YU-2 Cre pseudovirus challenge)
coding for the receptors required for HIV-1 entry (hCD4 and
hCCR5) (Figure 2A). Following challenge with HIV-1 Cre pseudo-
virus, infection was quantified noninvasively by whole-body
imaging.
Mouse IgG subclass variants of 3BNC117 (mouse IgG1,
mouse IgG1 D265A, and mouse IgG2a) with differential capacity
to engage mouse FcgRs were administered (intraperitoneal, i.p.)
to luciferase reporter mice 24 hr prior to challenge with HIV-1YU-2
Cre pseudovirus. Comparison of the in vivo activity of different
mouse-human chimeric IgG subclass variants of 3BNC117 re-
vealed that the mouse IgG2a variant exhibited significantly
enhanced in vivo protective activity compared to its mouse
IgG1 and mouse IgG1 D265A counterparts (Figures 2B–2D).
Titration of the mAb dose revealed a specific range at which
mouse IgG2a exhibits improved in vivo activity; lower doses
(<1 mg) were not sufficient to prevent infection, whereas at higher
ones (100 mg), Fab-mediated neutralization activity dominates
masking any Fc effector contribution by mouse IgG2a subclass
variant (Figure 2C). Minimal activity was observed in isotype sub-
class variants of a non-HIV-1 reactive antibody (mGO53 [Warde-
mann et al., 2003]) (Figure 2E).CTo provide further evidence on the role of Fc-FcgR interactions
in the augmented in vivo protective activity of mouse IgG2a sub-
class variant of 3BNC117, its activity was assessed in twomouse
strains (crossed to ROSA-Luc) deficient for all classes of mouse
FcgRs: (1) FcgRanull encompassing targeted deletion of the all
mouse FcgR a chain-encoding genes (Fcgr1, Fcgr2b, Fcgr3,
and Fcgr4) (described and characterized in Smith et al. [2012])
and (2) Fcer1g/, Fcgr2b/ double-knockout mice for the
FcR g chain (required for the expression of all activating FcgRs)
and FcgRIIb-encoding genes. In contrast to wild-type (WT)
mice, comparison of the in vivo activity between mouse IgG2a
and mouse IgG1 D265A (FcgR null binding variant, exhibiting
only Fab-mediated activity) revealed no significant difference
in FcgR-deficient mice (FcgRanull, Figure 2F; Fcer1g/,
Fcgr2b/, Figure 2G), suggesting the involvement of FcgR-,
but not complement-mediated pathways in the enhanced in vivo
activity of 3BNC117 mouse IgG2a subclass variant.
Given the selective binding specificity of mouse IgG2a for acti-
vating FcgR, like FcgRIV and FcgRI, it is likely that viral opsoni-
zation by mouse IgG2a mAbs promotes their clearance by
circulating or tissue-resident FcgR-expressing effector cells,
contributing thereby to the observed enhanced in vivo activity
of mouse IgG2a mAbs. To determine the consequences of
mAb-mediated virus opsonization on clearance and subsequent
prevention of viral entry, circulating viral content was measured
in mice that have been administered either mouse IgG2a or
mouse IgG1 D265A (FcgR null binding) variants of 3BNC117.
Serum viral RNA was quantified by reverse-transcriptase quan-
titative PCR, and as it is evident in Figures 2H and 2I, significantly
lower viral titers were observed on day 1 and 3 postinfection in
mice that have previously received mouse IgG2a 3BNC117
compared to untreated (PBS) or mouse IgG1 D265A-treated
ones. These findings suggest that the observed enhancement
in FcgR-mediated in vivo protective activity of mouse IgG2a
3BNC117 could be attributed to improved clearance of mAb-
opsonized viruses prior to infection.
To determine whether the enhanced in vivo activity observed
for the mouse IgG2a subclass variant of the broadly neutralizing
anti-CD4bs mAb 3BNC117 also extends to mAbs with low
neutralization potency, we assayed mouse subclass variants of
1-74, a poorly neutralizing, anti-CD4bs mAb (IC50 > 50 mg/ml
for HIV-1YU-2). Mouse IgG2a 1-74 mAb exhibited significantly
augmented in vivo activity compared to mouse IgG1 and mouse
IgG1 D265A variants (Figure 3A)—an effect that was not evident
in FcgR-deficient (FcgRanull) mice (Figure 3B). Similar to anti-
CD4bs mAbs, increased in vivo effector activity of mouse
IgG2a subclass variants was observed in mAbs with differential
epitope specificities (CD4bs, V1/2, and V3), indicating that
augmented FcgR-mediated in vivo protective activity is indepen-
dent of Fab-antigen interactions relating to epitope targeting
(Figures 3C–3E). Furthermore, no differences in mAb serum con-
centration at the time of HIV-1 Cre pseudovirus challenge were
observed among the various mouse IgG subclass variants, con-
firming that the enhanced in vivo activity of mouse IgG2a mAbs
could not be attributed to differential mAb biodistribution (Fig-
ure S2). These findings suggest a clear role for Fc effector activity
of anti-HIV-1 mAbs in preventing viral entry and revealed that se-
lective engagement of activating, but not inhibitory FcgR byell 158, 1243–1253, September 11, 2014 ª2014 Elsevier Inc. 1245
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Figure 2. Mouse IgG2a Subclass Variants of 3BNC117 Exhibit Improved in Vivo Activity
The in vivo activity ofmouse-human chimeric Fc variants of 3BNC117was assessed in amousemodel for HIV entry (Pietzsch et al., 2012) using luciferase reporter
mice.
(A) Infection with HIV-1YU-2 Cre pseudovirus was accomplished by adenoviral-mediated expression of human CD4 and CCR5.
(B–D) Enhanced in vivo activity was observed for mouse IgG2a subclass variants of 3BNC117, compared to mouse IgG1 and mouse IgG1 D265A. (B) indicates
representative in vivo luminescence image; (C) indicates 3BNC117 variants administered at different doses (0.1–100 mg/ml, i.p.); data are presented as the
mean ± SEM, n = 5 per group, *p < 0.05 mouse IgG2a versus mouse IgG1 D265A; (D) indicates 3BNC117 administered at a single concentration (50 mg, i.p.).
n = 5–6 per group, and ***p < 0.001 compared to PBS-treated group.
(E) Isotype subclass variants of a non-HIV-1 reactive mAb (mGO53, 500 mg) displayed no protective activity; n = 5–6 per group.
(F and G) No significant difference in the in vivo activity was observed between mouse IgG2a and mouse IgG1 D265A (FcgR null binding) variants of 3BNC117
(50 mg, i.p.) in two strains of FcgR-deficient mice. (F) indicates FcgRanull; (G) indicates Fcer1g/; Fcgr2b/. NS, not significant mouse IgG2a versus PBS or
mouse IgG1 D265A.
(H and I) Enhanced in vivo activity of mouse IgG2a 3BNC117 was accompanied by improved virus clearance. Serum pseudovirus content (1 [H] and 3 [I] days
following HIV-1YU-2 Cre pseudovirus infection) was determined using a qRT-PCR-based assay specific forCre. Data are presented as the mean ± SEM. *p < 0.05
and **p < 0.01 compared to PBS/mIgG1 D265A groups; n = 4 mice per group.mouse IgG2a subclass mAbs, induces increased in vivo protec-
tive activity—an effect not dependent on antibody potency or
epitope specificity.
Development of Human IgG1 Anti-HIV-1 bNAbs with
Selectively Enhanced FcgR Binding Profile through Fc
Domain Engineering
Given our finding using WTmice that preferential engagement of
activating, but not inhibitory, FcgRs augmented the in vivo bNAb1246 Cell 158, 1243–1253, September 11, 2014 ª2014 Elsevier Inc.activity, human IgG1 Fc domain variants of anti-HIV-1 bNAbs
(3BNC117, 10-1074 [Mouquet et al., 2012], and PG16) were
generated to selectively engage with enhanced activity human
activating FcgRs, like human FcgRIIIa and FcgRIIa, with minimal
modulation of FcgRIIb binding capacity (Table S4 and Figures 4A
and 4B). Additionally, an Fc domain variant of hIgG1 that is defi-
cient in binding to all classes of human and mouse FcgRs was
generated.WT hIgG1 and Fc domain variants (enhanced for acti-
vating FcgR binding: G236A/S239D/A330L/I332E [GASDALIE]
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Figure 3. Enhanced In Vivo Activity of Mouse IgG2a Fc Variants of Anti-HIV-1 mAbs Is Not Restricted by Epitope Specificity or Neutralization
Potency
Mouse Fc domain variants of anti-HIV-1 mAbs were administered to luciferase reporter mice (i.p. 3BNC60, 3BNC117: 50 mg; 1-74: 500 mg; 1-79: 350 mg;
3BNC176: 150 mg; PGT121, PG16: 200 mg; mGO53: 500 mg) 24 hr prior to HIV-1YU-2 Cre pseudovirus infection, and their in vivo activity was assessed by whole-
body imaging.
(A and B) Significant enhancement in the in vivo activity of mouse IgG2a subclass variants of 1-74 was observed in (A)WTmice, but not in (B) FcgR-deficientmice;
n = 5–6 per group, and *p < 0.05 compared to PBS-treated group; NS: not significant.
(C–E) Increased in vivo potency of the mouse IgG2a variant was also evident for mAbs targeting different epitopes.
(C and D) (C) PGT121, n = 6 per group, and **p < 0.01 compared to PBS; (D) overview of the in vivo activity of the different mouse IgG Fc subclass variants of the
various anti-HIV-1 mAbs. Maximal infection obtained from PBS-injected mice was used to calculate percentage of infection; data are presented as the mean ±
SEM; n = 5–7 mice per group, and *p < 0.05 and**p < 0.01 compared to the respective mouse IgG1 D265A mAb variant.
(E) Quantitative comparison of infection (infection index: averaged percentage of infection of mouse IgG2a- or mouse IgG1 treated over mouse IgG1 D265A)
between the Fc domain variants standardized to the mouse IgG1 D265A variant of each respective mAb.
See also Figure S2.[Smith et al., 2012]; FcgR null binding: G236R/L328R [GRLR]
[Horton et al., 2010]) of 3BNC117, 10-1074, and PG16 were ex-
pressed in mammalian cells and characterized in terms of their
affinity and specificity for HIV-1 Env (Figures 4C and S3 and
Table S5) and in vitro neutralization (Figure 4D and Table S6).
No differences in their antigen specificity and in vitro neutraliza-
tion activity were detected among the various Fc domain vari-
ants, despite their differential capacity to engage the various
human and mouse FcgRs (Figure 4A and Table S4).
Fc-Optimized Variants of Anti-HIV-1 Human IgG1 bNAbs
Exhibit Improved In Vivo Activity
Although our findings suggest that preferential engagement of
activating FcgRs throughmouse IgG2a subclass variants modu-
lates the in vivo bNAb activity, the use of a murine model system
does not allow direct comparison of mAb Fc effector activity in
humans. To overcome this problem, we have recently developed
a mouse model in which the mouse FcgRs were deleted and allCthe human FcgRs were expressed as transgenes, faithfully reca-
pitulating the human-specific FcgR expression pattern and di-
versity (Smith et al., 2012). These mice have been previously
characterized and successfully used for the study of human
IgG Fc effector activity in vivo (Bournazos et al., 2014; DiLillo
et al., 2014; Smith et al., 2012). Luciferase reporter mice were
crossed to FcgR humanized mice, and the activity of anti-
HIV-1 human IgG1 bNAbs and Fc domain variants was evalu-
ated. Comparison of their in vivo activity revealed that the Fc
domain variant of 3BNC117 with enhanced binding capacity
to engage activating FcgRs (GASDALIE) also demonstrated
increased protective activity compared to WT human IgG1
3BNC117 (Figures 5A and 5B). Furthermore, 3BNC117 GRLR
Fc variant, which exhibitsminimal binding to all classes of human
FcgRs, displayed significantly reduced in vivo protective activity
compared to WT human IgG1 and to the GASDALIE Fc variant.
These effects were not accompanied by any differences in the
mAb biodistribution, with comparable serum IgG levels detectedell 158, 1243–1253, September 11, 2014 ª2014 Elsevier Inc. 1247
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Figure 4. Generation and Characterization of
Fc Domain Variants of Anti-HIV-1 mAbs with
Selective FcgR Binding Capacity
(A–D) Fc domain variants (GRLR and GASDALIE) of
hIgG1 anti-HIV-1 mAbs with differential FcgR affinity
(A and B); see also Table S4. (A) IgG Fc domain
variant affinity against different classes and common
allelic variants of human and mouse FcgRs; (B) fold
enhancement in the affinity of Fc domain variants
compared to WT human IgG1 for human FcgRs.
(n.b.: no binding) were generated and characterized
in terms of (C) antigen specificity (see also related
Figure S3) and (D) in vitro neutralization activity.
(C) Binding of anti-HIV-1 mAb hIgG1 Fc domain var-
iants to gp160DctYU-2- or GFP-expressing HEK293T
cells was assessed by flow cytometry. Data repre-
sent the geometricmean fluorescence intensity (Geo
MFI) from three independent experiments.
(D) In vitro neutralization activity (against HIV-1YU-2)
of human Fc domain variants of anti-HIV-1 mAbs
was determined by a standardized TZM-bl assay
(Montefiori, 2005) (see also Tables S5 and S6).at the time of virus challenge irrespective of the Fc variant (Fig-
ure S4A). Furthermore, no in vivo protective activity was
observed when a non-HIV-1 reactive mAb (mGO53) was used
as control (Figure 5C). These findings clearly highlight the contri-
bution of Fc-FcgR interactions in the in vivo mAb activity using a
mouse system that closely resembles the unique pattern of hu-
man FcgR structural and functional diversity.
In an attempt to provide additional evidence on the importance
of Fc effector pathways for the in vivo activity of anti-HIV-1
mAbs, the activity of Fc domain variants of anti-HIV-1 mAbs
was evaluated in two different mouse models of HIV-1 infection
that recapitulate the complete virus cycle of HIV-1. Human IgG1
Fc domain variants of the 10-1074 bNAb exhibiting differential
binding capacity for human and mouse FcgRs (GRLR: FcgR
null binding; GASDALIE: improved FcgR binding) were adminis-
tered (200 mg, i.v.) to NRG (nonobese diabetic [NOD], Rag1/,
Il2rg/) mice prior to transfer of in vitro HIV-1YU-2-infected hu-
man CD4+ T cells (2 3 107, i.v.). Measurement of plasma viral
load (24 hr postinoculation of infected cells) revealed a substan-
tial reduction in viremia in mice that have previously received 10-
1074 GASDALIE, but not the GRLR Fc variant (Figure 5D).
Concurrent administration of bNAbs targeting different epi-
topes of HIV-1 Env has been shown to confer sustained suppres-
sion of viremia in humanized mouse models of HIV-1 infection
(Horwitz et al., 2013; Klein et al., 2012b). This model has been
previously used to evaluate the therapeutic potential of several
anti-HIV-1 bNAbs and involves the use of NRG mice reconsti-
tuted with human fetal liver-derived CD34+ hematopoietic stem
cells (HSCs) (Klein et al., 2012b). To determine the contribution
of the Fc effector function in the in vivo therapeutic activity of
broadly neutralizing anti-HIV-1 mAbs, HIV-1YU-2-infected hu-
manized mice were treated with a combination of 3BNC117,
10-1074, and PG16 (200 mg per mAb, every 5–7 days) either as
GASDALIE or GRLR Fc variants, which exhibit enhanced or
diminished FcgR binding capacity, respectively (Table S4).
Both variants exhibited comparable binding capacity to human
or mouse FcRn/b2 microglobulin and similar in vivo half-life pro-
file (Figures S4B–S4F). In comparison to mice treated with the1248 Cell 158, 1243–1253, September 11, 2014 ª2014 Elsevier Inc.FcgR null binding (GRLR) variant of 3BNC117, 10-1074, and
PG16, GASDALIE-treated mice exhibited faster and sustained
reduction in viral load with a significantly higher proportion of
them demonstrating durable (lasting > 3 consecutive weeks)
viremia suppression (viremia levels below detection limit [<800
copies/ml]) (Figures 6A–6D). Sequencing of HIV-1 gp120 from
GASDALIE-treated mice that failed to completely suppress
viremia (3/12) revealed recurrent mutations in some of the
bNAb-recognizing epitopes within gp120 (Figure S5). Further-
more, when we monitored viremia for several weeks (up to 8)
following cessation of bNAb treatment in decaying serum anti-
HIV-1 bNAb concentration, GASDALIE-treated mice exhibited
suppressed viremia even when serum bNAb concentration
dropped below 3 mg/ml; an average concentration previously
determined when viral rebound occurred in mice treated with
the same combination (3BNC117, 10-1074, and PG16) of WT
hIgG1 bNAbs (Halper-Stromberg et al., 2014). In summary, these
findings strongly support that the in vivo protective activity of
anti-HIV-1 mAbs is highly dependent upon Fc-FcgR interactions
and that Fc-optimized bNAb variants with enhanced FcgR bind-
ing capacity exhibited improved in vivo protective activity.
DISCUSSION
Since the first clinical use of mAbs for the treatment of inflamma-
tory and neoplastic disorders, it became apparent that Fc
effector activity plays an essential role in the therapeutic poten-
tial of an antibody (Nimmerjahn and Ravetch, 2012). For
example, the therapeutic outcome of a number of mAbs was
associated with allelic variants of FcgR genes that affect the re-
ceptor capacity for IgG binding (Nimmerjahn and Ravetch,
2012). This ever-increasing body of evidence suggests a signifi-
cant role of FcgR-mediated interactions in the in vivo activity of
antibody-based therapeutics.
Despite previous evidence on the role of FcgR effector activity
in clinical progression of AIDS (Forthal et al., 2007) and mAb-
mediated pre-exposure prophylaxis (Hessell et al., 2007), the
contribution of Fc effector function to the in vivo activity of
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Figure 5. Enhancement of the In Vivo Activity of Anti-HIV-1 mAbs
through Fc Domain Engineering for Selective FcgR Engagement
(A–C) The in vivo activity of 3BNC117 Fc variants with differential FcgRs
binding capacity was assessed in luciferase reporter mice crossed to FcgR
humanized mice. WT IgG1, GRLR, or GASDALIE variants of 3BNC117 were
administered (i.p.) to mice ([A] low dose, 20 mg, **p < 0.01 compared toWT and
***p < 0.001 compared to GRLR; [B] high dose, 100 mg, ***p < 0.001/**p < 0.01
compared to GRLR; [C] isotype control [mGO53], 100 mg) 24 hr prior to
infection with HIV-1 Cre pseudovirus. Maximal infection obtained from PBS-
injected mice was used to calculate percentage of infection, and data are
presented as the mean ± SEM. n = 5–6 group.
(D) Fc domain variants (GRLR and GASDALIE) of 10-1074 mAb were admin-
istered (200 mg, i.v.) to NRGmice prior to transfer of in vitro HIV-1YU-2-infected
human CD4+ T cells (2 3 107, i.v.). Measurement of plasma viral load (24 hr
postinoculation of infected cells) revealed a substantial reduction in viremia in
mice that have previously received 10-1074 GASDALIE. n = 3–5 mice per
group, **p < 0.01 compared to PBS-treated mice. NS, not significant.
See also Figure S4.anti-HIV-1 bNAbs has not yet been determined, mainly due to
the lack of an in vivo model system for HIV-1 entry that recapit-
ulates the unique pattern of human FcgR expression and diver-
sity. Current strategies to measure the neutralization activity of
anti-HIV-1 mAbs involve well-established in vitro assays (TZM-
bl cell-based assays), which generally offer no information on
the antibody effector activity because they lack FcgR-express-
ing effector leukocytes. Likewise, in vitro conditions of assays
commonly used for the study of antibody Fc effector activity
fail to reproduce the in vivo complexity that governs FcgR-medi-
ated pathways. Nonhuman primates have been widely used for
the in vivo study of HIV-1 infection, and a role for Fc effector func-
tion in the mAb-mediated antiviral activity has been previously
demonstrated (Hessell et al., 2007). However, given the relative
limitations that nonhuman primate models present, the precise
role of Fc-FcgR interactions in the neutralizing activity of anti-
HIV-1 bNAbs cannot be systematically studied. For example,
nonhuman primate models display substantial FcgR genomic
variation, and their FcgR functional and structural characteristics
are not concordant with human FcgR physiology (Nguyen et al.,
2011) (S.B. and J.V.R., unpublished data).CIt is therefore likely that any evidence on the role of Fc effector
activity obtained through the use of in vitro assays or nonhuman
primate in vivo models might not represent accurately the
complexity and diversity of human FcgR physiology. Indeed,
recent studies indicated that the relative contribution of FcgR-
mediated pathways to the in vivo mAb activity diverges greatly
between humans and nonhuman primates, and many mecha-
nistic insights obtained from one species were not replicated
to the other. For example, although Fc-engineered glycovariants
of b12 (nonfucosylated b12) with enhanced affinity for human
and rhesus FcgRIIIa demonstrated substantially improved
in vitro Fc effector activity in NK cell activation and ADCC and
ADCVI assays using human FcgR-expressing effector leuko-
cytes, there was no augmentation in the capacity of this mAb
variant to protect macaques against mucosal SHIV challenge
(Moldt et al., 2012). Similarly, in another study (Dugast et al.,
2014), passive transfer of antibodies failed to protect macaques
following SHIV challenge, despite their exceptional in vitro ADCC
activity using human-derived effector leukocytes.
To precisely delineate the FcgR-mediated mechanisms that
participate in the in vivo activity of anti-HIV-1 bNAbs, we utilized
a recently developed mouse model for HIV-1 entry (Pietzsch
et al., 2012), as well as human leukocyte-reconstituted mice,
as models for bNAb-mediated therapy. In agreement with previ-
ous observations on the requirement of Fc effector activity of
anti-HIV-1 mAbs to confer pre- and postexposure prophylaxis
in macaques and humanized mice, respectively (Halper-Strom-
berg et al., 2014; Hessell et al., 2007), our study demonstrated
a key role for FcgR-mediated interactions in the in vivo activity
of anti-HIV-1 bNAbs. Assessment of the in vivo activity of
mouse-human chimeric anti-HIV-1 bNAbs in WT mice revealed
significantly augmented activity of mouse IgG2a subclass vari-
ants through enhanced opsonization and clearance of viral par-
ticles from circulation. These protective effects of mouse IgG2a
reflect the capacity of this subclass to interact with activating
FcgRs like FcgRIV and FcgRI (Table S1 and Figure 1A). Indeed,
in several mouse models of antibody-mediated cellular cytotox-
icity, such differences in the capacity of the various mouse IgG
subclasses to engage activating or inhibitory FcgRs have been
shown to be predictive of the in vivo mAb activity (Abboud
et al., 2010; DiLillo et al., 2014; Li and Ravetch, 2011; Nimmer-
jahn et al., 2010; Nimmerjahn and Ravetch, 2005).
Because engagement of activating, but not inhibitory, FcgRs
conferred augmented in vivo protective activity, we developed
Fc domain variants of human IgG1 to exhibit selectively
enhanced binding capacity to activating human FcgRs. As the
amino acid backbone of the Fc domain is the main determinant
for Fc-FcgR interaction, introduction of certain mutations in the
Fc region that participates in the FcgR binding interface modu-
lates the capacity of an IgG molecule to interact with FcgRs
(Lazar et al., 2006; Shields et al., 2001). This approach has
been previously employed by several groups to successfully
generate antibodies with improved Fc effector functions,
including antibody-dependent cellular cytotoxicity (ADCC) and
opsonization through enhancement of Fc-FcgR interactions
(Bournazos et al., 2014; DiLillo et al., 2014; Heider et al., 2011;
Horton et al., 2010; Lazar et al., 2006; Smith et al., 2012).
Similarly, in our study, Fc domain variants (GASDALIE) ofell 158, 1243–1253, September 11, 2014 ª2014 Elsevier Inc. 1249
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Figure 6. In Vivo Therapeutic Activity of
Anti-HIV-1 bNAbs Requires FcgR Effector
Function in HIV-1-Infected Humanized Mice
(A and B) Humanized NRG mice were infected
with HIV-1YU-2 and, 3 weeks postinfection (viral
load > 104 copies/ml), were treated for 6 weeks
(red-shaded area) with a combination of
3BNC117, 10-1074, and PG16 mAb Fc domain
variants exhibiting either enhanced binding ca-
pacity for activating FcgRs (GASDALIE; [A]) or
diminished binding to all classes of FcgRs
(GRLR; [B]). Plasma viral load was quantified
at weekly intervals to assess the capacity of
anti-HIV-1 bNAb Fc variants to suppress
viremia. Each line represents an individual
mouse, and dotted lines represent mice with
evidence of recurrent mutations in mAb-target-
ing epitopes of gp120 (Figure S5). Quantitation
of serum bNAb concentration (right axis, red
line) following cessation of antibody therapy
revealed sustained viremia suppression in
GASDALIE-treated mice at limiting anti-HIV-1
bNAb serum levels.
(C and D) Comparison of their in vivo therapeutic activity revealed that GASDALIE mAb variants induced a significant and faster reduction in viral load (C),
resulting in substantially lower proportion of mice with viremia levels above the detection limit (>800 copies/ml). (D) n = 12 per group; **p < 0.05 and ***p < 0.01
GASDALIE versus GRLR-treated groups.
See also Figure S5.anti-HIV-1 bNAbs that exhibited enhanced binding capacity for
activating human FcgRs, such as FcgRIIa and FcgRIIIa (Figures
4A and 4B), also presented augmented in vivo protective and
therapeutic activity compared to WT or FcgR null binding vari-
ants (GRLR). Despite the obvious limitations that animal models
present to reflect precisely the complexity of human HIV-1 infec-
tion (duration of infection, host immune responses, and alter-
ations in effector cellular compartments), our findings strongly
support the importance of activating FcgR engagement in the
bNAb-mediated antiviral protection.
In summary, our findings clearly indicate that the in vivo activ-
ity of anti-HIV-1 mAbs is largely determined by Fc domain inter-
actions. Indeed, the in vivo protective activity of anti-HIV mAbs
correlates precisely with their capacity to engage activating
FcgRs, but not with their in vitro neutralization activity. For
example, poorly neutralizing anti-HIV-1 mAbs, like 1-74, exhibit
potent in vivo activity when expressed as Fc subclass variants
capable for activating FcgR engagement (Figure 3A). Likewise,
antibodies with exceptionally high neutralization potency readily
lose their in vivo therapeutic activity when their capacity for FcgR
engagement is diminished (Figure 6). These findings highlight the
substantial role of FcgR-mediated mechanisms in the in vivo
protective activity of anti-HIV-1 bNAbs, completely revising our
current understanding of the mechanisms of antibody-mediated
viral neutralization. Contrary to the typical notion that viral
neutralization by antibodies is simply the result of blocking viral
entry via Fab-antigen interactions, our observations strongly
suggest that Fc-mediated effector functions contribute substan-
tially to the activity of anti-HIV-1 mAbs.
Understanding the significance of Fc-FcgR interactions in the
protective activities of anti-HIV-1 antibodies would provide use-
ful insights for the development of vaccination strategies to elicit
antibodies with enhanced capacity to activate FcgR-mediated1250 Cell 158, 1243–1253, September 11, 2014 ª2014 Elsevier Inc.pathways. Additionally, in view of the recent successful thera-
peutic application of several anti-HIV-1 mAbs with exceptionally
broad and potent neutralizing activity to effectively control viral
replication in nonhuman primate (Barouch et al., 2013; Shingai
et al., 2013) and humanized mouse models (Horwitz et al.,
2013; Klein et al., 2012b), optimization of their in vivo therapeutic
efficacy is necessary to accelerate their potential clinical use for
the treatment of HIV-1 infection in humans. Although previously
employed strategies to successfully generate anti-HIV bNAbs
with increased potency mainly focused on enhancing the spec-
ificity and breadth of Fab-antigen interactions (Diskin et al.,
2011), in the present report, we suggest that modifications in
the Fc domain to modulate its selective interaction with different
FcgRs can greatly influence the protective activity of bNAbs.
These findings suggest strategies for designing and developing
therapeutic antibodies with improved in vivo efficacy for the pre-
vention and treatment of HIV-1 infection in humans.
EXPERIMENTAL PROCEDURES
A detailed description of the experimental procedures is provided in the
Extended Experimental Procedures section.
In Vivo HIV-1 Pseudovirus Infection and Bioluminescence Imaging
Mice were injected with 1011 adenoviral particles i.v. (AdV-hCCR5-2A-hCD4)
48 hr prior to infection with HIV-1 Cre pseudovirus. For in vivo infection,
HIV-1YU-2 pseudovirus (3–5.5 3 1010) was injected through the lateral vein.
On day 4 postinfection with pseudovirus, mice were anesthetized with 2%
(v/v) isoflurane and injected i.p. with 4.5 mg D-Luciferin (Regis Technologies).
For FcgR humanized mice, mice were anesthetized with 2% (v/v) isoflurane
and ketamine/xylazine (75 mg and 15 mg/kg of body weight, respectively;
i.p.), and the peritoneal cavity was surgically exposed prior to in vivo imaging.
Bioluminescence was acquired using an IVIS Lumina II platform (Caliper Life
Sciences), and data were analyzed using Living Image imaging software
(Caliper Life Sciences).
Viral Load Quantification
For the quantification of serum HIV-1YU-2 Cre pseudovirus levels, viral RNA
was purified from serum (100 ml), and Cre RNA content of the samples was
quantitated by one-step real time RT-PCR. Plasma HIV-1 viral load was quan-
tified as previously described (Horwitz et al., 2013; Klein et al., 2012b). The
lower limit of detection for this assay was previously determined to be 800
copies/ml (Klein et al., 2012b). Additional details are presented in the Extended
Experimental Procedures section.
In Vitro HIV-1 Infection of CD4+ T Cells
Human PBMCs were purified from peripheral blood leukocyte units (New York
Blood Center) using Ficoll density gradient medium (Ficoll-Paque Plus, GE
Healthcare), followed by isolation of CD4+ T cells by negative magnetic immu-
noselection (human CD4+ T cell isolation kit [negative selection], Miltenyi
Biotech). Purified CD4+ T cells (5 3 106 cells/ml in complete RPMI media)
were stimulated with PHA (5 mg/ml; Sigma) and recombinant human IL-2
(50 U/ml; Peprotech) for 48 hr prior to infection with HIV-1YU-2 (50 ng p24/
107 cells for 4 hr). Following infection, cells were incubated in fresh
complete RPMI media, supplemented with IL-2 (50 U/ml) for 60 hr. Prior to in-
jection (2 3 107, i.v.) to NRG mice, cells were washed twice in PBS.
In Vivo HIV-1 Infection and mAb Treatment
Humanized NRGmice were generated by intrahepatic human CD34+ HSCs in-
jection of sublethally irradiated neonatal NRG mice, as previously described
(Horwitz et al., 2013; Klein et al., 2012b). Mice (>10 weeks) with a measurable
human CD45+ graft were infected following i.p. injection of HIV-1YU-2
(57.5 ng p24). Viral load was quantified 3 weeks postinfection, and mice with
viral loads > 104 copies/ml were included in treatment experiments. Antibodies
(3BNC117, 10-1074, PG16, 200 mg of each mAb, 600 mg total in PBS contain-
ing 2 mg IVIG, Gammagard) were administered subcutaneously (s.c.) every
5 days for the first 2 weeks and weekly thereafter for 6 weeks. This dosing
schedule was sufficient to maintain serum levels of each mAb > 10 mg/ml
over the course of the treatment (Figure S4F). IVIG (5 mg) was administered
s.c. 6 hr prior to the first antibody injection. No neutralization activity or
gp140 reactivity was observed for the IVIG preparation, as assessed by TZMbl
assay and anti-gp140 ELISA, respectively.
Statistical Analysis
Results from multiple experiments are presented as mean ± SEM. One-way
ANOVA or Kruskal-Wallis test was used to test for differences in the mean
values of quantitative variables, and where statistically significant effects
were found, post hoc analysis using Bonferroni t test or Dunn’s multiple com-
parison test was performed, respectively. For infection curve comparison,
viremia rates (sustained aviremia was defined as VL < 800 copies/ml for > 3
consecutive weeks) were analyzed with the log rank (Mantel-Cox) test.
Data were analyzed with Graphpad Prism software (Graphpad) and p values
of < 0.05 were considered to be statistically significant.
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